Merck

Merck

Preço: 119.05

Empresa e modelo de negócios

Merck & Co., Inc. is a global healthcare company that develops and manufactures pharmaceuticals, vaccines, biologics, and animal health products. Its core products include treatments for cancer, diabetes, and infectious diseases, with significant revenue generated from its oncology and vaccine segments. The company also focuses on research and development to innovate new therapies and improve existing ones.

Perfil de investimento

The stock presents a balanced investment profile, appealing to investors seeking a combination of growth and income through dividends. With a moderate dividend yield and a focus on innovation, it may attract those interested in stable returns while also considering potential capital appreciation.

Site oficial

Métricas fundamentais (experimental)

EPS (TTM) — lucro por ação dos últimos 12 meses, $
3.56 OK
Receita QoQ — crescimento da receita trimestre contra trimestre
-0.2%
Surpresa de EPS
1.5% em linha
Volatilidade 20d
2.1% estável
Dividend yield
3.5% moderado última data ex-dividendo: 2026-06-15
Dados FMP / FinFeed atualizados: 2026-06-09
Rec.: Comprar Potencial: 67 Risco: 40 Atualizado: 2026-06-13 02:52
Como a recomendação funciona
Por que a IA pensa assim:
Stable dividend, but mixed momentum signals present uncertainty.

Acompanhar no portfólio

Gráfico de preço

Recomendação da IA Previsão do analista Evento de calendário Sinal positivo Sinal negativo Neutro / atualização Manter / informativo B My buy S My sell
Mudanças na recomendação da IA
Data Antes Depois Motivo
2026-06-09 02:45 Manter Comprar Stable dividend, moderate growth, cautious market sentiment.
2026-06-01 02:45 Comprar Manter Solid dividend yield, but mixed momentum signals.
2026-05-24 02:45 Manter Comprar Strong momentum and solid dividend yield support growth.
Previsões de analistas
Data Analista Action Alvo Preço na época
2026-06-02 10:48 Guggenheim Atualizar — → 140 115.21
2026-05-01 16:03 Morgan Stanley Preço-alvo elevado 109 → 112 112.47
2026-03-12 11:05 Wells Fargo Preço-alvo elevado — → 150 116.22
Merck Redwire Eli Lilly

The Pharmaceutical Industry Embraces Space: Drug Development in Low Earth Orbit Gains Momentum

The shift of pharmaceutical development to lower Earth orbit represents a significant evolution in the space economy, with the potential to enhance drug formulation and delivery methods. This trend could disrupt traditional pharmaceutical practices and create new investment opportunities as the space economy is projected to exceed $1 trillion by 2040.